Evidence map›Paper›PMID 33852832›Full record

ArticleImmunity2021

A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.

Bronwyn M Gunn, Richard Lu, Matthew D Slein, Philipp A Ilinykh, Kai Huang, Caroline Atyeo, Sharon L Schendel, Jiyoung Kim, Caitlin Cain, Vicky Roy and 15 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days.bioRxiv : the preprint server for biology · 2026
    Article
  4. CD4Nature immunology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 3 countries.

Bronwyn M GunnRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Richard LuRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Matthew D SleinRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Philipp A IlinykhDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Kai HuangDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Caroline AtyeoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Sharon L SchendelLa Jolla Institute for Immunology, La Jolla, CA, USA.
Jiyoung KimRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Caitlin CainRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Vicky RoyRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Todd J SuscovichRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Ayato TakadaResearch Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Peter J HalfmannDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin - Madison, Madison, WI, USA.
Yoshihiro KawaokaDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin - Madison, Madison, WI, USA.
Matthias G PauthnerDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA, USA.
Mambu MomohViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Augustine GobaViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Lansana KannehViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Kristian G AndersenDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA, USA; Scripps Research Translational Institute, La Jolla, CA, USA.
John S SchieffelinDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Donald GrantViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone; Ministry of Health and Sanitation, Freetown, Sierra Leone.
Robert F GarryDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA.
Erica Ollmann SaphireLa Jolla Institute for Immunology, La Jolla, CA, USA. Electronic address: erica@lji.org.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX, USA. Electronic address: abukreye@utmb.edu.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: galter@partners.org.
Ragon Institute of MGH, MIT and Harvard · USUniversity of Sierra Leone · SLGalveston College · USLa Jolla Institute for Immunology · USScripps Research Institute · USTulane University · USUniversity of Wisconsin–Madison · USHokkaido University · JP

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6M
NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI142790
6 · The paper itself

Abstract

Protective Ebola virus (EBOV) antibodies have neutralizing activity and induction of antibody constant domain (Fc)-mediated innate immune effector functions. Efforts to enhance Fc effector functionality often focus on maximizing antibody-dependent cellular cytotoxicity, yet distinct combinations of functions could be critical for antibody-mediated protection. As neutralizing antibodies have been cloned from EBOV disease survivors, we sought to identify survivor Fc effector profiles to help guide Fc optimization strategies. Survivors developed a range of functional antibody responses, and we therefore applied a rapid, high-throughput Fc engineering platform to define the most protective profiles. We generated a library of Fc variants with identical antigen-binding fragments (Fabs) from an EBOV neutralizing antibody. Fc variants with antibody-mediated complement deposition and moderate natural killer (NK) cell activity demonstrated complete protective activity in a stringent in vivo mouse model. Our findings highlight the importance of specific effector functions in antibody-mediated protection, and the experimental platform presents a generalizable resource for identifying correlates of immunity to guide therapeutic antibody design.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralAntibody-Dependent Cell CytotoxicityAntibody FormationEbolavirusFemaleHEK293 CellsHemorrhagic Fever, EbolaHumansImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsImmunoglobulin GMiceMice, Inbred BALB CReceptors, FcAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsImmunoglobulin GReceptors, FcADCCantibody engineeringcomplementEbola virusFc effector functionhumoral immunityinfectious diseasesmonoclonal antibody therapeuticsphagocytosis

Identifiers

PMID33852832
PMCPMC8111768
OpenAlexW3154849380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.